ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

ClearLeaf’s GotaBlanca Demonstrates Superior Performance in Cornell University Apple and Grape Trials

By: Get News
Comprehensive trials carried out by Cornell AgriTech confirm that GotaBlanca delivers excellent pathogen control, matching or exceeding conventional treatments in apples and grapes

San José, Costa Rica - November 7, 2025 - ClearLeaf, a Costa Rican company with proven success in formulating non-toxic agricultural products for crop protection, today announced that its GotaBlanca fungicide and bactericide proved highly effective in controlling pathogens in grapes and apples in field trials conducted by Cornell University’s Cornell AgriTech. The apple and grape field trials demonstrated that ClearLeaf's flagship product matched or outperformed currently recommended products in controlling both fungal and bacterial diseases, with its favorable safety profile for crops and the environment.

In the apple trials, GotaBlanca achieved fire blight, scab, and powdery mildew disease control that significantly outperformed incumbents, including streptomycin antibiotics, which have been banned in organic production since 2014. This positions GotaBlanca as a viable organic-compatible alternative. When used in rotation programs, GotaBlanca matched or exceeded complex conventional programs while maintaining excellent crop health, with no damage or stress to plants across all applications.

In the grape trials, GotaBlanca treatment in single product applications achieved excellent severity control of downy mildew and black rot, surpassing the grower standard. Rotation strategies boosted control even further, exceeding conventional programs by achieving superior control without the need for complex mixtures of synthetic crop protection products.

Dr. Kerik Cox at Cornell AgriTech noted: "The apple trials provided valuable insights into GotaBlanca's potential as an alternative to conventional disease management strategies. In our fire blight trials, GotaBlanca achieved control levels of 90% or greater for both blossom and shoot blight, significantly outperforming streptomycin antibiotics—results that are particularly relevant given the increasing restrictions on agricultural antibiotic use. What stood out was the performance in rotation programs for scab and powdery mildew, where it matched or exceeded complex conventional programs while maintaining excellent crop health. The absence of phytotoxicity across all apple applications represents a meaningful advantage for growers."

Dr. Katie Gold and Dave Combs in the Grape Sensing, Pathology, and Extension Laboratory at Cornell AgriTech, commented: "Our grape trials evaluated GotaBlanca across four major disease pressures, and the results demonstrate its versatility as both a standalone treatment and rotation partner. For downy mildew, GotaBlanca alone achieved 86% severity control on clusters, surpassing our grower standard, with rotation strategies pushing control above 89%. The black rot trials were particularly interesting—GotaBlanca rotated with biologicals provided equivalent cluster incidence control to the grower standard (systemic synthetic fungicide), which is impressive given the pressure in our trials is incredibly high. What makes these findings significant is that GotaBlanca can deliver this level of control across multiple diseases and grape varieties, while offering flexible integration into existing IPM programs and supporting sustainable viticulture practices.”

Dr. Agustín Büchert, CSO and Co-founder of ClearLeaf, remarked: "These comprehensive Cornell trials represent a milestone in validating what we've observed across dozens of controlled experiments and with our grower customers in Latin America — effective, broad-spectrum crop protection doesn't require a compromise between performance and safety. Significantly, GotaBlanca as a single standalone product matched or exceeded the control levels achieved by applications involving multiple conventional products. This translates directly into cost savings for farmers — they can achieve superior disease control with fewer products instead of purchasing and tank-mixing multiple products at each application, while also reducing chemical loads. Combined with zero phytotoxicity, superior crop health metrics, and in several cases better yields than conventional treatments, GotaBlanca delivers both economic and agronomic advantages. For farmers navigating increasing restrictions on antibiotics and synthetic fungicides, GotaBlanca offers a path forward that doesn't sacrifice disease control or profitability."

GotaBlanca is currently registered for use or sale in select international markets. GotaBlanca is not currently registered for use or sale in the U.S., a U.S. EPA registration is planned. GotaBlanca stands out as a broad-spectrum fungi-bactericide with a favorable safety profile for crops and the environment, It does not cause microbial resistance, enhances plant growth, aligns with regenerative agriculture practices, and can be applied at any stage of the growing cycle.

For more information about ClearLeaf Inc and its portfolio of agricultural innovations, visit https://www.clearleaf.ag

About ClearLeaf

ClearLeaf Inc is dedicated to empowering farmers with safe solutions that optimize crop production while minimizing worker, consumer and environmental impact. Through innovative technology and a commitment to sustainability, we are transforming agricultural practices worldwide.

Media Contact
Company Name: ClearLeaf Inc
Contact Person: Media Relations
Email: Send Email
Country: Costa Rica
Website: https://www.clearleaf.ag

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.